Biotech Archives - Page 13 of 733

1 minute read

MangoRx Introduces “MOJO” Pharmaceutical Compounded Formula Featuring Enclomiphene Citrate And Pregnenolone For Treatment Of Low Testosterone And Male Hormone Imbalances; Sold Exclusively On MangoRx’s Website On A Subscription Basis At A Price Of $199…

June 4, 8:01 AM

MOJO to be offered as an Oral Dissolvable Tablet (ODT) marketed to younger male demographic as an alternative to PRIME Testosterone Replacement Therapy (TRT)Dallas, Texas, June 04, 2024 (GLOBE NEWSWIRE) --

MGRX

2 minute read

Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder

By Vandana Singh

June 4, 7:02 AM

Spruce Biosciences collaborates with HMNC Brain Health to advance tildacerfont, a precision therapeutic for major depressive disorder, using the Cortibon Genetic Selection Tool.

SPRB

2 minute read

Johnson & Johnson Ordered To Pay $260M In Latest Talc Trial

By Benzinga Neuro

June 4, 1:58 AM

The ruling comes as J&J continues to pursue a proposed $6.48 billion settlement of most talc-related lawsuits through a prepackaged bankruptcy.

JNJ

2 minute read

FibroGen Stock Is Surging After The Bell: What’s Going On?

By Adam Eckert

June 3, 4:48 PM

FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial supply agreement with Regeneron.

FGEN

1 minute read

Inogen’s Study Demonstrating The Association Of Portable Oxygen Therapy With Decreased Mortality And Increased Cost-Effectiveness Ratio Published In The Journal Pulmonary Therapy

By Benzinga Newsdesk

June 3, 4:20 PM

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today shared the results of a study published in the journal Pulmonary Therapy,

INGN

1 minute read

FibroGen Inks Clinical Trial Supply Agreement With Regeneron Pharmaceuticals To Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 And FG-3175, In Combination With LIBTAYO In Upcoming Clinical Trials

By Benzinga Newsdesk

June 3, 4:09 PM

FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumorsFibroGen to evaluate FG-3175,

FGEN

1 minute read

Ascendis Pharma To Present New Data And Updated Results From Phase 1/2 IL-Believe Trial At ASCO 2024

By Benzinga Newsdesk

June 3, 4:05 PM

- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ in combination with TransCon TLR7/8 Agonist exhibited

ASND

1 minute read

Scholar Rock To Present New Data From SRK-181 Phase 1 DRAGON Trial At ASCO 2024 Annual Meeting

By Benzinga Newsdesk

June 3, 4:01 PM

Promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patientsAnalysis of baseline biomarker data in clear cell renal cell carcinoma (ccRCC) patients reveals a doubling

SRRK

1 minute read

Johnson & Johnson Announces Results From A Subgroup Analysis Of The Phase 3 CARTITUDE-4 Study Showing CARVYKTI Improved Progression-Free Survival And Deepened Responses Versus Two Standard Therapies For Patients With Functional High-Risk Multiple Myelo…

By Benzinga Newsdesk

June 3, 3:58 PM

73 percent reduction in risk of disease progression or death seen with CARVYKTI® in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy1CHICAGO, June 3, 2024

JNJ

1 minute read

Johnson & Johnson Announces Data From Phase 3 PERSEUS Study Showing DARZALEX-Based Regimens Significantly Improve Clinical Outcomes In Both Transplant-Eligible And -Ineligible Patients Who Are Newly Diagnosed With Multiple Myeloma

By Benzinga Newsdesk

June 3, 3:51 PM

88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-negativity for longer than one year with DARZALEX FASPRO® (daratumumab and

JNJ